Drug Profile

Research programme: cancer therapeutics - CorMedix/NanoProteagen

Alternative Names: CRMD 005/vincristine; CRMD-005; Taurolidine/vincristine - CorMedix; Vincristine/taurolidine - CorMedix

Latest Information Update: 28 Mar 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CorMedix; National Cancer Institute (USA)
Developer CorMedix
Class Antineoplastics
Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Deoxyribonuclease I stimulants; Lipopolysaccharide inhibitors; Thrombin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Neuroblastoma
New Molecular Entity No

28 Mar 2022 No recent reports of development identified for preclinical development in Cancer(In children, In infants) in USA
28 Mar 2022 No recent reports of development identified for preclinical development in Neuroblastoma(In children, In infants) in USA
26 Apr 2019 9265445- relevant info already covered

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com